(Q37765581)

22 August 2017

1 reference

title

Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer (English)

1 reference

22 August 2017

1 reference

1 reference

Josep M Del Campo

1

1 reference

22 August 2017

Eva Muñoz-Couselo

series ordinal

2

1 reference

22 August 2017

Isabella Diaz de Corcuera

series ordinal

3

1 reference

22 August 2017

Ana Oaknin

series ordinal

4

1 reference

22 August 2017

publication date

1 June 2010

1 reference

Expert Review of Anticancer Therapy

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

795-805

1 reference

Ovarian cancer: epidemiology, biology, and prognostic factors

22 August 2017

cites work

1 reference

Second-line treatment of ovarian cancer

21 January 2018

1 reference

The role of cytoreductive/debulking surgery in ovarian cancer

21 January 2018

1 reference

A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.

21 January 2018

1 reference

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

21 January 2018

1 reference

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

21 January 2018

1 reference

Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.

21 January 2018

1 reference

Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.

21 January 2018

1 reference

Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).

21 January 2018

1 reference

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

Antiangiogenic drugs in ovarian cancer.

21 January 2018

1 reference

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin

21 January 2018

1 reference

Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.

21 January 2018

1 reference

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

21 January 2018

1 reference

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

21 January 2018

1 reference

Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft

21 January 2018

1 reference

The combination of yondelis and cisplatin is synergistic against human tumor xenografts

21 January 2018

1 reference

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

21 January 2018

1 reference

Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.

21 January 2018

1 reference

Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.

21 January 2018

1 reference

Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer

21 January 2018

1 reference

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

21 January 2018

1 reference

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

21 January 2018

1 reference

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

21 January 2018

1 reference

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

21 January 2018

1 reference

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

21 January 2018

1 reference

Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts

21 January 2018

1 reference

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer

21 January 2018

1 reference

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

21 January 2018

1 reference

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

21 January 2018

1 reference

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

21 January 2018

1 reference

Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up

21 January 2018

1 reference

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

21 January 2018

1 reference

Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-base

21 January 2018

1 reference

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (A

21 January 2018

1 reference

Targeting signal transduction pathways in colorectal cancer--more than skin deep

21 January 2018

1 reference

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

21 January 2018

1 reference

In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II.

21 January 2018

1 reference

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

21 January 2018

1 reference

Hypersensitivity reactions: an increasingly recognized toxicity of platinum agents

21 January 2018

1 reference

Diagnosis and management of epithelial ovarian cancer

21 January 2018

1 reference

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

21 January 2018

1 reference

21 January 2018

1 reference

Tuberin haploinsufficiency is associated with the loss of OGG1 in rat kidney tumors

21 January 2018

1 reference

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

21 January 2018

1 reference

Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.

21 January 2018

1 reference

Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma

21 January 2018

1 reference

Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature

21 January 2018

1 reference

Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.10.59

1 reference

22 August 2017

1 reference